US Stock MarketDetailed Quotes

BBIO BridgeBio Pharma

Watchlist
  • 30.920
  • +0.060+0.19%
Close Mar 28 16:00 ET
  • 31.000
  • +0.080+0.26%
Post 19:35 ET
5.70BMarket Cap-7827P/E (TTM)

About BridgeBio Pharma Company

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Company Profile

SymbolBBIO
Company NameBridgeBio Pharma
Listing Date06/27/2019
Issue Price17.00
Founded2015
CEODr. Neil Kumar, PhD
MarketNASDAQ
Employees556
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address3160 Porter Drive,Suite 250
CityPalo Alto
ProvinceCalifornia
CountryUnited States of America
Zip Code94304
Phone1-650-391-9740

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Neil Kumar, PhD
  • Director; President and Chief Executive Officer of the Company and Eidos Therapeutics
  • 6.67M
  • Dr. Brian C. Stephenson, PhD
  • Secretary, Chief Financial Officer and Principal Accounting Officer
  • 2.96M
  • Dr. Charles J. Homcy,M.D.
  • Lead Independent Director and Chairman of Pharmaceuticals
  • 992.60K
  • James C. Momtazee
  • Director and Senior Advisor, Transactions
  • 600.00K
  • Dr. Frank P. McCormick, D.Sc.
  • Director
  • --
  • Jennifer E. Cook
  • Director
  • 600.00K
  • Fred Hassan
  • Independent Director
  • 600.00K
  • Dr. Randal W. Scott,PhD
  • Independent Director
  • 600.00K
  • Dr. Eric Aguiar, M.D.
  • Independent Director
  • 600.00K
  • Ali J. Satvat
  • Independent Director
  • 1.32M
  • Douglas A. Dachille
  • Independent Director
  • 600.00K
  • Ronald J. Daniels
  • Independent Director
  • 600.00K
  • Dr. Andrew W. Lo
  • Independent Director
  • 600.00K
  • Dr. Hannah A. Valantine, M.D.
  • Independent Director
  • 600.00K
  • Andrea John Ellis
  • Independent Director
  • 600.00K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg